GSK plc 6-K, filed Aug 16, 2022
GSK plc (GSK)
6-K
2022-08-16
For: 2022-08-16
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on August 16, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 16 August 2022, London UK
GSK completes acquisition of Affinivax, Inc.
GSK plc (LSE/NYSE: GSK) today announced it has completed the
acquisition of Affinivax, Inc (Affinivax), a clinical-stage
biopharmaceutical company based in Cambridge (Boston,
Massachusetts). Affinivax has pioneered the development of a novel
class of vaccines, the most advanced of which are next-generation
pneumococcal vaccines.
As previously announced, the acquisition of Affinivax aligns with
GSK's strategy of building a strong portfolio of specialty
medicines and vaccines. It includes a next-generation 24-valent
pneumococcal vaccine candidate (AFX3772), currently in phase II
development, which is based on the highly innovative Multiple
Antigen Presenting System (MAPSTM)
platform technology.
A 30-plus valent pneumococcal candidate vaccine is also in
pre-clinical development.
The MAPSTM technology supports
higher valency than conventional conjugation technologies,
potentially enabling broader coverage against prevalent
pneumococcal serotypes and generating higher antibody responses
against many individual serotypes than current pneumococcal
vaccines.
Tony Wood, Chief Scientific Officer, GSK, said: "Affinivax's exciting pneumococcal vaccine
candidates, the potentially disruptive MAPs technology and their
fantastic scientific talent, further strengthen our pipeline of
novel vaccines and presence in the Boston
area".
In the adult phase I/II clinical trials, AFX3772 was well tolerated
in participants and demonstrated good immune responses compared to
the current standard of care. In July 2021, the US Food and Drug
Administration granted Breakthrough Therapy designation for AFX3772
to prevent S. pneumoniae invasive disease and pneumonia in adults
50 years and above. Preparations for the start of the phase III
program are underway. Phase II clinical trials started in June 2022
to assess the use of the vaccine in the paediatric
population.
Financial considerations
Under the terms of the agreement, GSK has acquired 100% of the
outstanding shares of Affinivax. The acquisition comprised an
upfront payment of $2.1 billion paid upon closing and two potential
milestone payments of $0.6 billion to be paid upon the achievement
of certain paediatric clinical development milestones. The
transaction was subject to customary closing conditions, including
the expiration or early termination of the waiting period under the
Hart-Scott- Rodino Anti-Trust Improvements Act of 1976. GSK will
account for the transaction as a business combination.
Pneumococcal disease
Pneumococcal disease is an umbrella term used to describe any
infection caused by the bacteria Streptococcus
pneumoniae, a leading cause of
acute bacterial infections worldwide. It has a broad clinical
spectrum including bloodstream infections (sepsis), pneumonia,
meningitis, and other milder diseases such as sinusitis and otitis
media. A broadly recognized unmet medical need remains despite the
availability of current vaccines. Pneumococcal pneumonia causes an
estimated 150,000 hospitalisations each year in the United States;
pneumococcal meningitis and bacteremia killed approximately 3,250
people in the United States in 2019[1].
MAPSTM technology
platform
Multiple Antigen Presenting System (MAPS) is a novel and highly
efficient vaccine technology platform that enables the precise,
high-affinity binding of pathogen-derived polysaccharides and
proteins of immune-relevance into a single vaccine. Immunisation
with the resulting polysaccharide-protein complexes induces a broad
and potentially protective B-cell (antibody) response to the
polysaccharides and a separate B-cell and T-cell immune response to
the proteins. The distinctive plug-and-play nature of
MAPSTM enables
the targeting of a broad range of infectious
diseases.
The initial use of the technology has been directed primarily
toward preventing pneumococcal disease. Applicability of the
technology has also been demonstrated for additional infectious
disease pathogens, including those that cause hospital-acquired
infections.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
|
|
|
|
|
|
|
|
Cautionary
statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered
in England & Wales:
No. 3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8 9GS
[1] US Centers for Disease
Control and Prevention, Fact facts - pneumococcal disease.
Available here: https://www.cdc.gov/pneumococcal/about/facts.html
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
16, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|